Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Operating Leases (2019 - 2025)

Historic Operating Leases for Editas Medicine (EDIT) over the last 8 years, with Q3 2025 value amounting to $13.6 million.

  • Editas Medicine's Operating Leases fell 3861.05% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year decrease of 3861.05%. This contributed to the annual value of $20.4 million for FY2024, which is 1637.95% down from last year.
  • As of Q3 2025, Editas Medicine's Operating Leases stood at $13.6 million, which was down 3861.05% from $15.0 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Operating Leases ranged from a high of $32.9 million in Q4 2022 and a low of $9.3 million during Q3 2022
  • Moreover, its 5-year median value for Operating Leases was $20.5 million (2024), whereas its average is $19.9 million.
  • As far as peak fluctuations go, Editas Medicine's Operating Leases tumbled by 5249.51% in 2022, and later surged by 16713.12% in 2023.
  • Quarter analysis of 5 years shows Editas Medicine's Operating Leases stood at $16.1 million in 2021, then surged by 104.52% to $32.9 million in 2022, then dropped by 25.84% to $24.4 million in 2023, then fell by 16.38% to $20.4 million in 2024, then tumbled by 33.44% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q3 2025, $15.0 million for Q2 2025, and $18.0 million during Q1 2025.